共 50 条
Cellular Therapy for Fanconi Anemia: The Past, Present, and Future
被引:16
|作者:
MacMillan, Margaret L.
[1
]
Hughes, Mark R.
[2
]
Agarwal, Suneet
[3
,4
,5
,6
,7
]
Daley, George Q.
[3
,4
,5
,6
,7
]
机构:
[1] Univ Minnesota, Dept Pediat, Div Pediat Hematol Oncol & Blood & Marrow Transpl, Blood & Marrow Transplant Program, Minneapolis, MN 55455 USA
[2] Appl Genom Technol Ctr Michigan, Genesis Genet Inst, Detroit, MI USA
[3] Childrens Hosp Boston, Howard Hughes Med Inst, Manton Ctr Orphan Dis Res, Stem Cell Transplantat Program,Div Pediat Hematol, Boston, MA USA
[4] Dana Farber Canc Inst, Boston, MA 02115 USA
[5] Brigham & Womens Hosp, Div Hematol, Boston, MA 02115 USA
[6] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA
[7] Harvard Stem Cell Inst, Boston, MA USA
关键词:
BONE-MARROW-TRANSPLANTATION;
PLURIPOTENT STEM-CELLS;
APLASTIC-ANEMIA;
DONORS;
CYCLOPHOSPHAMIDE;
IRRADIATION;
DISEASE;
BLOOD;
ENGRAFTMENT;
GENERATION;
D O I:
10.1016/j.bbmt.2010.11.027
中图分类号:
R5 [内科学];
学科分类号:
1002 ;
100201 ;
摘要:
Allogeneic hematopoietic cell transplantation (HCT) remains the only proven curative therapy for the hematologic manifestation of Fanconi anemia (FA). Over the past 2 decades, major advances have been made such that transplant outcomes have markedly improved. With the development of in vitro fertilization and preimplantation genetic diagnosis, HLA-matched sibling donor umbilical blood transplantation may be an option for more patients with FA. Recently, the use of pluripotent stem cells has been explored as a novel approach to model the hematopoietic developmental defects in FA, and to provide a potential source of autologous stem cells that can be genetically manipulated and used to generate corrected hematopoietic progenitors. Biol Blood Marrow Transplant 17: S109-S114 (2011) (C) 2011 American Society for Blood and Marrow Transplantation
引用
收藏
页码:S109 / S114
页数:6
相关论文